These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31862182)

  • 1. Safety of regadenoson for vasodilation in cardiac MRI stress tests.
    Bastarrika G; Ezponda A; Baizan AG; Calvo M; Pueyo JC; Gavira JJ; Caballeros M
    Radiologia (Engl Ed); 2020; 62(3):213-221. PubMed ID: 31862182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR.
    Muñiz-Sáenz-Diez J; Ezponda A; Caballeros M; de la Fuente A; Gavira JJ; Bastarrika G
    Int J Cardiovasc Imaging; 2023 Sep; 39(9):1765-1774. PubMed ID: 37354385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac magnetic resonance imaging myocardial perfusion reserve index in heart transplant patients.
    Jiménez-Jaso JM; Ezponda A; Sáenz-Diez JM; Caballeros M; Rábago G; Bastarrika G
    Radiologia (Engl Ed); 2020; 62(6):493-501. PubMed ID: 32493651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial Stress Perfusion MRI: Experience in Pediatric and Young-Adult Patients Following Arterial Switch Operation Utilizing Regadenoson.
    Noel CV; Krishnamurthy R; Masand P; Moffett B; Schlingmann T; Cheong BY; Krishnamurthy R
    Pediatr Cardiol; 2018 Aug; 39(6):1249-1257. PubMed ID: 29748700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regadenoson: a new myocardial stress agent.
    Al Jaroudi W; Iskandrian AE
    J Am Coll Cardiol; 2009 Sep; 54(13):1123-30. PubMed ID: 19761931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.
    Noel CV; Krishnamurthy R; Moffett B; Krishnamurthy R
    Pediatr Radiol; 2017 Mar; 47(3):280-289. PubMed ID: 28035425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of regadenoson stress testing in patients with pulmonary hypertension.
    Moles VM; Cascino T; Saleh A; Mikhova K; Lazarus JJ; Ghannam M; Yun HJ; Konerman M; Weinberg RL; Ficaro EP; Corbett JR; McLaughlin VV; Murthy VL
    J Nucl Cardiol; 2018 Jun; 25(3):820-827. PubMed ID: 27896702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients.
    Kazmirczak F; Nijjar PS; Zhang L; Hughes A; Chen KA; Okasha O; Martin CM; Akçakaya M; Farzaneh-Far A; Shenoy C
    J Cardiovasc Magn Reson; 2019 Jan; 21(1):9. PubMed ID: 30674318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
    Brink HL; Dickerson JA; Stephens JA; Pickworth KK
    Pharmacotherapy; 2015 Dec; 35(12):1117-23. PubMed ID: 26684552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
    AlJaroudi WA; Alraies MC; Cerquiera MD; Jaber WA
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):341-8. PubMed ID: 23208701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.
    Townsend R; Desai A; Rammelsberg D; Kowalski D; Simmons N; Kitt TM
    J Nucl Cardiol; 2017 Feb; 24(1):57-65. PubMed ID: 26607361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
    Salgado-Garcia C; Jimenez-Heffernan A; Ramos-Font C; Lopez-Martin J; Sanchez-de-Mora E; Aroui T; Lopez-Aguilar R; Rivera-de-Los-Santos F; Ruiz-Frutos C
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):283-6. PubMed ID: 27160774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison.
    Cury RC; Kitt TM; Feaheny K; Akin J; George RT
    J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.
    Lazarus JJ; Saleh A; Ghannam M; Aaronson K; Colvin M; Pagani F; Koelling T; Corbett JR; Weinberg RL; Murthy VL; Konerman MC
    J Nucl Cardiol; 2020 Jun; 27(3):943-948. PubMed ID: 30483958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.
    Zhao G; Serpllion S; Shryock J; Messina E; Xu X; Ochoa M; Belardinelli L; Hintze TH
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):467-73. PubMed ID: 19033827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of regadenoson CMR.
    Nguyen KL; Bandettini WP; Shanbhag S; Leung SW; Wilson JR; Arai AE
    Eur Heart J Cardiovasc Imaging; 2014 Jul; 15(7):753-60. PubMed ID: 24451179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.